Aquestive Therapeutics, Inc. (AQST)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 4
Do Nothing: fundamentalScore is 2 (below required floor of 3); strategy requires fundamentalScore ≥ 3 before any bullish entry.
Company overview
Aquestive Therapeutics, Inc. is a pharmaceutical company specializing in the development and commercialization of products for unmet medical needs in the U.S. and international markets. Its portfolio includes products like Sympazan, Suboxone, Zuplenz, and Azstarys, with a focus on oral soluble film formulations. The company is also advancing a pipeline of drug candidates, including Libervant and Exservan.
Fundamental
weakThe company shows revenue improvement but remains cash-burning and reliant on regulatory outcomes.
Speculative fundamentals: recent SEC filings show strong year-over-year revenue improvement and a narrowing operating loss, but the company is still loss-making and consuming cash, with a stockholders’ deficit. A refinancing extended debt maturities and reduced near-term maturity pressure, but at a high floating-rate cost and with covenant constraints. The investment case remains heavily dependent on FDA/regulatory outcomes (notably Anaphylm after a CRL) rather than on a proven, self-funding operating model.
Sentiment
fairMedia sentiment is mildly constructive, but cash-burn concerns persist.
Near-term narrative is driven by announced positive Anaphylm human-factors/PK study results (Aug 10) alongside the Q2 update (Aug 11), leaving media tone mildly constructive but still mixed with cash-burn/“weak earnings” framing. 14d media sentiment is slightly positive (polarity_score ≈ +0.12) vs a neutral 30–90d baseline (≈0.00); no regulator-confirmed investigations surfaced and Reddit engagement is minimal.
Technical
goodShort-term technicals are positive, with price above key moving averages and strong trend indicators.
AQST earns a 4/5 technical score because the short-term trend is constructive and liquid: price is above the 20/50-day and 9/21-day moving-average stack, RSI is supportive, MACD has turned positive, and ADX is strong. The one clear blemish is that the stock still sits below the 200-day average and underneath nearby 4.39-4.44 resistance.
You’re looking at 2026-08-19 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.